- Home
- TCI vs CLLS Comparison
TCI vs CLLS Comparison
Compare TCI & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TCI | CLLS |
|---|---|---|
| Founded | 1983 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.7M | 384.3M |
| IPO Year | 1994 | 2014 |
Fundamental Metrics
Financial Performance| Metric | TCI | CLLS |
|---|---|---|
| Price | $35.23 | $3.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 3.4K | ★ 32.2K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 135.29 | N/A |
| EPS | ★ 1.60 | N/A |
| Revenue | ★ $49,060,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.98 |
| P/E Ratio | $22.14 | ★ N/A |
| Revenue Growth | ★ 4.23 | N/A |
| 52 Week Low | $26.96 | $1.33 |
| 52 Week High | $59.65 | $5.48 |
Technical Indicators
Market Signals| Indicator | TCI | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 40.46 | 52.47 |
| Support Level | $33.50 | $3.39 |
| Resistance Level | $47.17 | $4.48 |
| Average True Range (ATR) | 1.62 | 0.19 |
| MACD | -0.27 | 0.01 |
| Stochastic Oscillator | 0.13 | 46.35 |
Price Performance
Historical ComparisonAbout TCI Transcontinental Realty Investors Inc.
Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates in two business segments: the acquisition, development, ownership and management of multifamily properties; and the acquisition, development, ownership and management of commercial properties; which are office properties. The services for its commercial segment include rental of office space and other tenant services, including parking and storage space rental. The services for its multifamily segment include rental of apartments and other tenant services, including parking and storage space rental. the company derives maximum revenue from Multifamily Segment.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.